Tactile Systems Technology Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名4/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價24.00。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Tactile Systems Technology Inc評分
相關信息
行業排名
4 / 208
全市場排名
45 / 4582
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
5
分析師
買入
評級
20.500
目標均價
+55.07%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Tactile Systems Technology Inc亮點
亮點風險
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
公司代碼TCMD
公司Tactile Systems Technology Inc
CEODodd (Sheri L)
網址https://www.tactilemedical.com/
常見問題
Tactile Systems Technology Inc(TCMD)的當前股價是多少?
Tactile Systems Technology Inc(TCMD)的當前股價是 28.920。
Tactile Systems Technology Inc 的股票代碼是什麼?
Tactile Systems Technology Inc的股票代碼是TCMD。
Tactile Systems Technology Inc股票的52週最高點是多少?
Tactile Systems Technology Inc股票的52週最高點是30.240。
Tactile Systems Technology Inc股票的52週最低點是多少?
Tactile Systems Technology Inc股票的52週最低點是8.610。
Tactile Systems Technology Inc的市值是多少?
Tactile Systems Technology Inc的市值是645.95M。
Tactile Systems Technology Inc的淨利潤是多少?
Tactile Systems Technology Inc的淨利潤為16.96M。
現在Tactile Systems Technology Inc(TCMD)的股票是買入、持有還是賣出?
根據分析師評級,Tactile Systems Technology Inc(TCMD)的總體評級為買入,目標價格為20.500。
Tactile Systems Technology Inc(TCMD)股票的每股收益(EPS TTM)是多少
Tactile Systems Technology Inc(TCMD)股票的每股收益(EPS TTM)是0.773。